European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Business Wire India – Approval Based on Positive Results from the Phase 3 HD21 Trial for StageIIb with Risk Factors/III/IV Hodgkin Lymphoma – ADCETRIS-based Combination Demonstrated Superior Safety Profile and…